This startup detects nerve damage quickly

Ayati Devices develops portable tools for detecting diabetic foot risks early. Its system looks for reduced nerve sensitivity, poor circulation, abnormal pressure under the foot, and impaired blood flow in small vessels. Finding these changes matters because undetected problems can progress to ulcers and, eventually, amputation.

For example, Vibrasense tests sensitivity to vibration and temperature. Vasosense calculates ankle- and toe-brachial indices for leg circulation. Podiasense creates a pressure map that highlights heavy-load areas, while Angiocam uses lasers to display blood flow in small vessels. Together, these tests create one screening workflow.

The approach is designed for routine clinical screening rather than waiting for visible injury. The startup has deployed more than 10,000 devices across over 30 countries and targets more than 10,000 healthcare institutions across India and initial international markets. Earlier detection could help clinicians identify patients needing closer monitoring or care.

Each test examines a different warning sign. Vibration and temperature sensitivity indicate how well nerves detect stimuli. Reduced responses suggest impaired nerve function, which can allow injuries to go unnoticed. Blood-flow measurements show whether the leg and foot receive adequate circulation. Poor circulation can make healing more difficult.

Vibrasense measures vibration and temperature sensitivity. Vasosense calculates ankle-brachial and toe-brachial indices, comparing pressures to assess circulation in the legs. Podiasense produces a visual map of pressure beneath the foot, revealing areas repeatedly exposed to heavy loads. Angiocam uses laser technology to show real-time flow in small vessels.

Together, these measurements provide a broader picture than a single check. The article presents them as a combined screening workflow for diabetic foot complications. That matters because neuropathy and reduced circulation can remain undetected until an ulcer or other serious complication appears.

Ayati’s potential population is tied to the global diabetes burden. The article reports that 589 million adults worldwide live with diabetes, creating a large need for routine foot screening. Not every person would use the devices, but diabetic patients are the central population the technology is designed to support.

Its stated institutional target is more than 10,000 healthcare institutions across India and initial international markets. A typical high-volume customer could screen 1,000 to 3,000 or more patients each year. At about ₹150 per test, each such institution could generate recurring testing revenue of ₹1.5 lakh to ₹4.5 lakh annually, before device and software revenue.

Ayati has already deployed more than 10,000 medical devices across over 30 countries. The figures show both a broad addressable market and existing international reach, while the company’s target indicates where it plans to expand screening access.

Undetected diabetic neuropathy or reduced blood flow can allow foot damage to worsen without timely attention. Neuropathy may reduce a patient’s awareness of injury, while poor circulation is linked to inadequate blood supply. Together, these problems raise the risk of diabetic foot ulcers and serious complications.

The article gives a stark scale: up to 34% of people with diabetes develop foot ulcers during their lifetime because of undetected neuropathy or reduced blood flow. It also reports that one patient undergoes a diabetes-related limb amputation every 30 seconds. These figures show why early screening matters.

Ayati’s devices are intended to identify changes before they become severe clinical events. By checking nerve sensitivity, circulation, pressure, and small-vessel blood flow in one workflow, clinicians may find patients who need closer monitoring. The article does not claim the devices prevent every ulcer or amputation, but it positions screening as an early warning step.

Clinical validation matters because screening devices must produce useful results in healthcare settings, not only in prototypes. Hospitals can assess whether the instruments fit clinical workflows and support decisions about diabetic foot risk. Partnerships also expose the technology to experienced medical teams and varied patient populations.

Ayati partnered with AIIMS Delhi and Apollo Hospital for clinical validation. The company also secured partnerships with major hospital networks including Fortis, Aster, and Medicover. These relationships connect the devices with hospitals where patients can be screened and where the combined workflow can be evaluated in practice.

The article does not provide validation results or specific accuracy figures. Still, the partnerships are important as Ayati expands. Clinical validation can support trust among doctors and institutions, while hospital deployments offer practical evidence about adoption. The company reports more than 10,000 devices deployed across over 30 countries, suggesting that partnerships are already part of its scale-up strategy.

Doctors commonly screen diabetic foot nerve damage with a 10-gram monofilament, which tests protective sensation at several foot sites. They may also use a tuning fork for vibration, temperature or pinprick testing, and reflex examinations. Reduced responses can suggest peripheral nerve impairment, although interpretation depends on the clinical setting.

For circulation, clinicians can feel foot pulses and examine skin condition, temperature, and color. They may measure an ankle-brachial index with a blood-pressure cuff and Doppler device. Toe-brachial index testing and vascular ultrasound can provide additional information. These methods examine circulation without using Ayati’s portable instrument set.

These alternatives are established medical approaches based on general clinical knowledge; the source article does not describe them or compare their performance with Ayati’s devices. Ayati’s stated distinction is integration: its instruments combine nerve, circulation, pressure, and small-vessel blood-flow checks into one workflow.

Diabetes is a chronic condition in which the body does not make enough insulin or cannot use it effectively, causing blood glucose to remain too high. Over time, elevated blood sugar can damage nerves and blood vessels. This explanation uses established medical knowledge; the article focuses on the resulting foot complications rather than defining diabetes.

In the feet, nerve damage can reduce sensitivity to vibration, temperature, or injury. A person may not notice a wound or pressure point. Blood-vessel damage can reduce circulation, making tissue health and healing more difficult. Ayati’s tools address these risks by testing nerve function, leg circulation, under-foot pressure, and small-vessel blood flow.

The article reports that up to 34% of diabetic patients develop foot ulcers during their lifetime because of undetected neuropathy or reduced blood flow. That risk helps explain the value of routine screening. Ayati’s combined workflow is intended to identify warning signs before complications become severe, although the article provides no claim that it eliminates all risk.